CAPTOR CAPITAL CORP. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2018 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED)

Notice To Reader

The accompanying unaudited condensed interim consolidated financial statements of the Company have been prepared by and are the responsibility of management. The unaudited condensed interim consolidated financial statements have not been reviewed by the Company's auditors.

Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian Dollars)
Unaudited

	As at September 30, 2018	As at March 31, 2018
Assets		
Current		
Cash and cash equivalents	\$ 18,740,945	
Amounts receivable and prepaid expenses (Note 3)	883,353	455,056
Loan receivable (Note 4)	19,911,570	1,344,602
Other investments (Note 5)	2,244,661	2,936,757 37,081,734
Investment in MedMen Enterprises Inc. (Note 6) Investment in Chai Cannabis Inc. (Note 7)	12,425,000 7,833,026	37,001,734
Prepaid deposit (Note 14)	199,721	214,290
	62,238,276	63,329,281
Investment in LE Holdings Ltd. (Note 9)	47,182,930	7,500,000
Investment in I-5 Holdings Ltd. (Note 8)	47,102,930	* *
Investment in URU Metals Limited	-	1,223,083
Equipment	34,240	38,136
	\$ 109,455,446	72,090,500
Liabilities and Shareholders' Equity		
Liabilities		
Current		
Accounts payable and accrued liabilities (Note 17) Promissory note (Note 7)	\$ 2,198,513 \$ 934,370	3 1,426,375 -
	3,132,883	1,426,375
Shareholders' Equity		
Share capital (Note 9)	107,172,652	65,735,076
Warrants reserve	16,372,090	16,379,014
Contributed surplus	10,649,210	8,130,710
Deficit	(27,871,389)	(19,580,675)
	106,322,563	70,664,125
	\$ 109,455,446 \$	72,090,500

NATURE OF OPERATIONS (Note 1) SUBSEQUENT EVENTS (Note 19)

Condensed Interim Consolidated Statements of Loss and Comprehensive Loss (Expressed in Canadian Dollars)
Unaudited

	Three Months Ended September 30, 2018 2017			E	Months Ended ember 30, 2017
Investment income (loss)	•	05 070 <i>(</i>)		05 070 A	
Interest income Unrealized loss in other investments (Note 5) Unrealized gain in investment in MedMen	\$	25,978 \$ (465,480)	- \$ (354,310)	25,978 \$ (2,440,178)	(4,027,340)
Enterprise Inc. (Note 6) Realized (loss) gain in investment in MedMen		4,533,446	-	1,667,102	-
Enterprise Inc. (Note 6)		(1,327,276)	-	2,876,816	-
Total investment income (loss)		2,766,668	(354,310)	2,129,718	(4,027,340)
Expenses General and administrative expenses (Note 13)		(6,239,241)	(86,310)	(10,430,631)	(241,546)
Total expenses		(6,239,241)	(86,310)	(10,430,631)	(241,546)
Net loss for the period before foreign exchange: Foreign exchange (loss) gain		(3,472,573) (278,441)	(440,620) (2,332)	(8,300,913) 10,199	(4,268,886) 474
Net loss and comprehensive loss for the period	\$	(3,751,014) \$	(442,952) \$	(8,290,714) \$	(4,268,412)
Loss per share - basic (Note 12) Loss per share - diluted (Note 12)	\$ \$	(0.10) \$ (0.10) \$	(0.07) \$ (0.07) \$		(0.65) (0.65)

Condensed Interim Consolidated Statements of Cash Flows (Expressed in Canadian Dollars) Unaudited

	Ended September 30,			
	2018	2017		
Cash (used in) provided by:				
Operating Activities				
Net loss for the period	\$ (8,290,714)	\$ (4,268,412)		
Stock based compensation expense	2,518,500	-		
Unrealized loss in other investments	2,440,178	4,027,340		
Unrealized gain in investment in MedMen Enterprise Inc.	(1,667,102)	-		
Realized gain in investment in MedMen Enterprise Inc.	(2,876,816)	-		
Depreciation	3,896	4,914		
Changes in non-cash working capital items:				
Amounts receivable and prepaid expenses	(428,297)	(1,504)		
Loan receivable	(14,039,052)	-		
Accounts payable and accrued liabilities	772,138	603,934		
Prepaid deposit	14,569	(781)		
	(21,552,700)	365,491		
Financing activity				
Exercise of warrants	35,000	-		
	35,000	-		
Investing Activities				
Purchase of investment in Chai Cannabis Inc.	(5,710,934)	_		
Proceeds from sale of investment in MedMen Enterprises Inc.	24,672,737	-		
	18,961,803	-		
Change in cash and cash equivalents	(2,555,897)	365,491		
Cash and cash equivalents, beginning of period	21,296,842	26,034		
Cash and cash equivalents, end of period	\$ 18,740,945	\$ 391,525		

Six Months

Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Expressed in Canadian Dollars) Unaudited

	_	are pital	Warrant Reserve		Contributed Surplus	l Deficit	Total
Balance, March 31, 2017 Net loss for the period	\$ 21,61 -	8,953	\$ - -	\$	7,955,990 -	\$ (23,361,680) (4,268,412)	6,213,263 (4,268,412)
Balance, September 30, 2017	\$ 21,61	8,953	\$ -	\$	7,955,990	\$ (27,630,092)	\$ 1,944,851
Balance, March 31, 2018	\$ 65,73	5,076	\$ 16,379,014	. \$	8,130,710	\$ (19,580,675)	\$ 70,664,125
Common shares issued for the acquisition of I-5 Holding Ltd.	39,68	•	-		-	-	39,682,930
Common shares issued for acquisition of Chai Cannabis Inc.	•	7,722	-		-	-	1,187,722
Common shares issued for acquisition of investment		5,000	- (0.004		-	-	525,000
Common shares issued for exercise of warrants	4	1,924	(6,924	-)	- 0.540.500	-	35,000
Share based compensation Net loss for the period	-		-		2,518,500 -	(8,290,714)	2,518,500 (8,290,714)
Balance, September 30, 2018	\$107,17	2,652	\$ 16,372,090	\$	10,649,210	\$ (27,871,389)	\$106,322,563

Notes to Condensed Interim Consolidated Financial Statements Three and Six Months Ended September 30, 2018 (Expressed in Canadian Dollars, unless otherwise indicated) (Unaudited)

1. NATURE OF OPERATIONS

Captor Capital Corp. (the "Company" or "Captor") was incorporated under the laws of the Province of Ontario, Canada by Articles of Incorporation dated September 26, 2003. On June 2, 2017, the Company changed its name from NWT Uranium Corp. to Captor Capital Corp. The Company also delisted its common shares from the TSX Venture Exchange (the "Exchange") on June 1, 2017. The delisting of the Company's shares from the Exchange was done pursuant to a resolution approved by shareholders that was passed on December 16, 2016. On October 30, 2017, the common shares of Captor commenced trading on the Canadian Securities Exchange ("CSE") under the symbol "CPTR".

Effective October 3, 2018, the Company consolidated its common shares on a 20:1 basis. All references in the unaudited condensed interim consolidated financial statements have been adjusted to reflect this share consolidation.

The Company is a cannabis focused investment company. The objective of the Company is to provide its shareholders with long-term capital growth by investing in a portfolio of cannabis focused companies. The primary office is located at 4 King Street West, Suite 401, Toronto, Ontario, M5H 1B6, Canada.

The unaudited condensed interim consolidated financial statements were approved by the Board of Directors on November 29, 2018.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Statement of compliance

The Company applies International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations issued by the IFRS Committee ("IFRIC"). These unaudited condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting. Accordingly, they do not include all of the information required for full annual financial statements required by IFRS as issued by IASB and interpretations issued by IFRIC.

The policies applied in these unaudited condensed interim consolidated financial statements are based on IFRSs issued and outstanding as of November 29, 2018, the date the Board of Directors approved the statements. The same accounting policies and methods of computation are followed in these unaudited condensed interim consolidated financial statements as compared with the most recent annual consolidated financial statements for the year ended March 31, 2018, except as noted below. Any subsequent changes to IFRS that are given effect in the Company's annual consolidated financial statements for the year ending March 31, 2019 could result in restatement of these unaudited condensed interim consolidated financial statements.

Changes in accounting policies

(i) IFRS 9, Financial Instruments

Effective April 1, 2018, the Company adopted IFRS 9. In July 2014, the IASB issued the final publication of the IFRS 9 standard, which supersedes IAS 39, Financial Instruments: recognition and measurement. IFRS 9 includes revised guidance on the classification and measurement of financial instruments, new guidance for measuring impairment on financial assets, and new hedge accounting guidance. The Company has adopted IFRS 9 on a retrospective basis, however, this guidance had no impact on the Company's financial statements.

Notes to Condensed Interim Consolidated Financial Statements Three and Six Months Ended September 30, 2018 (Expressed in Canadian Dollars, unless otherwise indicated) (Unaudited)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Changes in accounting policies (continued)

(i) IFRS 9, Financial Instruments (continued)

Under IFRS 9, financial assets are classified and measured based on the business model in which they are held and the characteristics of their contractual cash flows. IFRS 9 contains the primary measurement categories for financial assets: measured at amortized cost, fair value through other comprehensive income ("FVTOCI") and fair value through profit and loss ("FVTPL").

Below is a summary showing the classification and measurement bases of our financial instruments as at April 1, 2018 as a result of adopting IFRS 9 (along with comparison to IAS 39).

Classification	IAS 39	IFRS 9
Cash	Loans and receivables (amortized cost)	Amortized cost
Amounts receivable	Loans and receivables (amortized cost)	Amortized cost
Investments	FVTPL	FVTPL
Accounts payable and accrued liabilities	Other financial liabilities (amortized cost)	Amortized cost

As a result of the adoption of IFRS 9, the accounting policy for financial instruments as disclosed in the Company's March 31, 2018 consolidated financial statements has been updated as follows:

Financial assets

Financial assets are classified as either financial assets at FVTPL, amortized cost, or FVTOCI. The Company determines the classification of its financial assets at initial recognition.

Financial assets recorded at FVTPL

Financial assets are classified as FVTPL if they do not meet the criteria of amortized cost or FVTOCI. Gains or losses on these items are recognized in profit or loss. Other investments and investments in I-5 Holdings Ltd., URU Metals Limited and MedMen Enterprises Inc. are designated as FVTPL.

Amortized cost

Financial assets are classified as measured at amortized cost if both of the following criteria are met and the financial assets are not designated as at fair value through profit and loss: 1) the object of the Company's business model for these financial assets is to collect their contractual cash flows; and 2) the asset's contractual cash flows represent "solely payments of principal and interest".

The Company's cash and receivables are classified as financial assets and measured at amortized cost.

Notes to Condensed Interim Consolidated Financial Statements Three and Six Months Ended September 30, 2018 (Expressed in Canadian Dollars, unless otherwise indicated) (Unaudited)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Changes in accounting policies (continued)

(i) IFRS 9, Financial Instruments (continued)

Financial liabilities

Financial liabilities are classified as either financial liabilities at fair value through profit or loss or at amortized cost. The Company determines the classification of its financial liabilities at initial recognition.

Amortized cost

Financial liabilities are classified as measured at amortized cost unless they fall into one of the following categories: financial liabilities at FVTPL, financial liabilities that arise when a transfer of a financial asset does not qualify for derecognition, financial guarantee contracts, commitments to provide a loan at a below-market interest rate, or contingent consideration recognized by an acquirer in a business combination.

The Company's accounts payable and accrued liabilities do not fall into any of the exemptions and are therefore classified as measured at amortized cost.

Transaction costs

Transaction costs associated with financial instruments, carried at FVTPL, are expensed as incurred, while transaction costs associated with all other financial instruments are included in the initial carrying amount of the asset or the liability.

Subsequent measurement

Instruments classified at FVTPL are measured at fair value with unrealized gains and losses recognized in profit or loss. Instruments classified at amortized cost are measured at amortized cost using the effective interest rate method. Instruments classified as FVTOCI are measured at fair value with unrealized gains and losses recognized in other comprehensive income. When an instrument at FVTOCI is sold, the accumulated gains or losses are reclassified from accumulated other comprehensive income (loss) directly to deficit.

Derecognition

The Company derecognizes financial liabilities only when its obligations under the financial liabilities are discharged, cancelled, or expired. The difference between the carrying amount of the financial liability derecognized and the consideration paid and payable, including any non-cash assets transferred or liabilities assumed, is recognized in profit or loss.

Expected Credit Loss Impairment Model

IFRS 9 introduced a single expected credit loss impairment model, which is based on changes in credit quality since initial application. The adoption of the expected credit loss impairment model had no impact on the Company's financial statements.

The Company assumes that the credit risk on a financial asset has increased significantly if it is more than 30 days past due. The Company considers a financial asset to be in default when the borrower is unlikely to pay its credit obligations to the Company in full or when the financial asset is more than 90 days past due.

The carrying amount of a financial asset is written off (either partially or in full) to the extent that there is no realistic prospect of recovery. This is generally the case when the Company determines that the debtor does not have assets or sources of income that could generate sufficient cash flows to repay the amounts subject to the write-off.

Notes to Condensed Interim Consolidated Financial Statements Three and Six Months Ended September 30, 2018 (Expressed in Canadian Dollars, unless otherwise indicated) (Unaudited)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Recent accounting pronouncements

Certain pronouncements were issued by the IASB or the IFRIC that are mandatory for future accounting periods. Many are not applicable or do not have a significant impact to the Company and have been excluded. The following recent accounting pronouncement has not yet been adopted.

Leases ("IFRS 16")

This standard introduces a single lessee accounting model and requires a lessee to recognize assets and liabilities for all leases with a term of more than 12 months, unless the underlying asset is of low value. A lessee is required to recognize a right-of-use asset representing its right to use the underlying asset and a lease liability representing its obligation to make lease payments.

This standard substantially carries forward the lessor accounting requirements of IAS 17, while requiring enhanced disclosures to be provided by lessors.

Other areas of the lease accounting model have been impacted, including the definition of a lease. Transitional provisions have been provided. The Company is currently evaluating the impact of IFRS 16 on its consolidated financial statements.

3. AMOUNTS RECEIVABLE AND PREPAID EXPENSES

	Se	As at eptember 30 2018	,	As at March 31, 2018
Sales tax receivable - Canada Other receivable Prepaid expenses	\$	266,674 125,576 491,103	\$	201,706 202,093 51,257
	\$	883,353	\$	455,056

4. LOAN RECEIVABLE

On March 5, 2018, the Company loaned I-5 Holdings Ltd. US\$1,042,812 (\$1,344,602). The loan bears no interest and is to be repaid on March 5, 2019. During the six months ended September 30, 2018, the Company loaned an additional US\$14,337,920 to I-5 Holdings Ltd. with the same terms as the original loan. As at September 30, 2018, Captor was owed a total of \$19,911,570 from I-5 Holdings Ltd.

Notes to Condensed Interim Consolidated Financial Statements Three and Six Months Ended September 30, 2018 (Expressed in Canadian Dollars, unless otherwise indicated) (Unaudited)

5. OTHER INVESTMENTS

Other investments consists of shares held in publicly listed and private companies. The fair market value as at September 30, 2018, was \$2,244,661 (March 31, 2018 - \$2,936,757).

The following table represents a continuity of other investments:

Balance, March 31, 2017 Additions Revaluation to fair market value	\$ 863,760 2,250,000 (177,003)
Balance, March 31, 2018 Additions Reclassification Revaluation to fair market value	2,936,757 525,000 1,223,083 (2,440,179)
Balance, September 30, 2018	\$ 2,244,661

6. INVESTMENT IN MEDMEN ENTERPRISES INC.

On February 26, 2018, Captor acquired 5,181,785 Class A Units of MM Enterprises USA, LLC ("MM Enterprises") for US\$23,000,000 (\$29,164,000). On May 28, 2018, MM Enterprises completed a business combination with MedMen Enterprises Inc. ("MedMen Enterprises"), a US based medical and adult use cannabis company listed in the CSE.

Captor Acquisition Corp. (the "Acquiror"), a subsidiary of Captor, in connection with the business combination, acquired 7,991,251 Class B Common Shares ("Class B Shares") of MM Can USA, Inc. ("PC Corp"), a subsidiary of MedMen Enterprises, pursuant to a contribution by the Acquiror of the same number of units of the LLC in exchange for such Class B Shares. Pursuant to the articles of incorporation of PC Corp, Captor may, from time to time, exchange its Class B Common Shares for Class B Subordinate Voting Shares of MedMen Enterprises on a one-for-one basis (the "Subordinate Voting Shares").

The Company received 7,991,251 Subordinate Voting Shares of MedMen Enterprises in exchange for the 5,181,785 Class A Units of MM Enterprises.

During the six months ended September 30, 2018, the Company sold 5,851,611 shares for cash of \$24,672,737 and \$4,527,916 for the extinguishment of a loan owed by I-5 Holdings Ltd. to MedMen Enterprises resulting in a gain of \$2,876,816.

Balance, September 30, 2018	\$ 12,425,000
Revaluation to fair market value	1,667,102
Additions Disposal	(26,323,836)
Balance, March 31, 2018	37,081,734
Revaluation to fair market value	7,917,734
Disposals	29,104,000
Balance, March 31, 2017 Additions	\$ - 29,164,000

As at September 30, 2018, the Company held 2,500,000 shares in MedMen Enterprises with a value of \$12,425,000.

Notes to Condensed Interim Consolidated Financial Statements Three and Six Months Ended September 30, 2018 (Expressed in Canadian Dollars, unless otherwise indicated) (Unaudited)

7. INVESTMENT IN CHAI CANNABIS INC.

On September 18, 2018, the Company completed the acquisition of Chai Cannabis Inc. ("Chai") for US\$6,015,000. Chai currently operates a fully adult use dispensary in Santa Cruz, California. The consideration of US\$6,015,000, was paid by US\$4,390,950 in cash (\$5,710,934), US\$721,800 (\$934,370) in the form of a promissory note and US\$902,250 (\$1,187,722) was paid by issuance of 383,135 shares of Captor.

8. INVESTMENT IN I-5 HOLDINGS LTD.

On December 20, 2017, Captor acquired 12,500,000 common shares of I-5 Holdings Ltd. ("I-5 Holdings") for \$5,000,000, representing approximately 21% of I-5 Holdings' issued and outstanding shares at the date of acquisition.

On February 26, 2018, Captor issued a total of 8,593,418 Captor Shares in escrow to acquire the remaining 79% of the I-5 Holdings securities. The Acquisition was completed on May 30, 2018 pursuant to an amended merger agreement dated February 16, 2018 between Captor and I-5 Holdings whereby the holders of common shares of I-5 ("I-5 Shares") received 0.13 common shares of Captor Capital Corp. ("Captor Share") in exchange for each I-5 Share.

As a result of the Acquisition, certain common share purchase warrants of I-5 Holdings are exercisable into 1,105,402 Captor Shares at an exercise price of \$5.00 per Captor Share and other common share purchase warrants of I-5 Holdings are exercisable into 187,545 Captor Shares at an exercise price of \$6.20 per Captor Share.

The fair value of the consideration to acquire I-5 Holdings is as follows:

Total consideration Revaluation to fair market value	44,682,930 2,500,000
Revaluation to fair market value Balance, September 30, 2018	2,500,000 \$ 47,182,930

Notes to Condensed Interim Consolidated Financial Statements Three and Six Months Ended September 30, 2018 (Expressed in Canadian Dollars, unless otherwise indicated) (Unaudited)

9. SHARE CAPITAL

a) Authorized

Unlimited number of common shares with no par value.

b) Issued and outstanding

Effective October 3, 2018, the Company consolidated its common shares on a 20:1 basis. All references in the unaudited condensed interim consolidated financial statements have been adjusted to reflect this share consolidation.

	Number of share	Number of shares		
Balance, March 31, 2017 and September 30, 2017	6,607,067	\$	21,618,953	
Balance, March 31, 2018	30,171,452	\$	65,735,076	
Common shares issued for acquisition of I-5 Holdings (Note 8)	8,593,418		39,682,930	
Common shares issued for acquisition of Chai Cannabis Inc. (Note 7)	383,135		1,187,722	
Common shares issued for acquisition of investment (Note 5)	187,500		525,000	
Common shares issued fro exercise of warrants	17,500		35,000	
Fair value of warrants exercised	-		6,924	
Balance, September 30, 2018	39,353,005	\$	107,172,652	

10. WARRANTS

The following table reflects the continuity of warrants for the periods presented:

	Number of warrants	Weighted average exercise price		
Balance, March 31, 2017 and September 30, 2017	-	\$	-	
Balance, March 31, 2018	14,709,692	\$	3.93	
Issued for acquisition of I-5 Holdings (Note 8) Exercised	1,292,946 (17,500))	5.17 2.00	
Balance, September 30, 2018	15,985,138	\$	4.03	

Notes to Condensed Interim Consolidated Financial Statements Three and Six Months Ended September 30, 2018 (Expressed in Canadian Dollars, unless otherwise indicated) (Unaudited)

10. WARRANTS (continued)

The Company had the following warrants outstanding at September 30, 2018:

Number of Warrants	Exercise Price	Expiry Date	
07.405	Ф Б ОО	March 7, 2010	
97,195	\$ 5.00	March 7, 2019	
200,199	\$ 5.00	May 2, 2019	
134,799	\$ 5.00	June 8, 2019	
103,300	\$ 5.00	August 2, 2019	
229,125	\$ 5.00	September 5, 2019	
68,819	\$ 5.00	October 3, 2019	
147,787	\$ 5.00	October 18, 2019	
124,177	\$ 5.00	November 2, 2019	
7,587,500	\$ 2.00	December 11, 2019	
187,545	\$ 6.20	February 5, 2020	
7,104,692	\$ 6.00	February 12, 2020	
15,985,138	\$ 4.03		

11. STOCK OPTIONS

The Company has a stock option plan for the purchase of common shares for its directors, officers, employees and other service providers. The aggregate number of common shares reserved for issuance under the stock option plan is 10% of the issued and outstanding common shares of the Company. The options are non-assignable and non-transferable and may be granted for a term not exceeding five years. The exercise price of the options is fixed by the Board of Directors of the Company at the time of grant, subject to all applicable regulatory requirements. The vesting term of the options is fixed by the Board of Directors of the Company at the time of grant and may vary from immediate vesting to up to 24 months.

The following table reflects the continuity of stock options for the periods presented:

	Number of stock options	_	ed average ise price	
Balance, March 31, 2017 and September 30, 2017	-	\$	-	
Balance, March 31, 2018 Options granted (i)	210,000 1,825,000	\$	2.00 6.00	
Balance, September 30, 2018	2,035,000	\$	5.59	

⁽ii) On August 8, 2018, the Company granted an aggregate of 1,825,000 options to officers, directors, employees and consultants of the Company. All stock options vested immediately and are exercisable at \$6.00 per common share for a period of 2 years. The fair value of \$2,518,500 was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: expected dividend yield of 0%; expected volatility of 110%; risk-free interest rate of 2.13% and an expected life of 2 years.

Notes to Condensed Interim Consolidated Financial Statements Three and Six Months Ended September 30, 2018 (Expressed in Canadian Dollars, unless otherwise indicated) (Unaudited)

11. STOCK OPTIONS (Continued)

The Company had the following stock options outstanding at September 30, 2018:

Outstanding options	Exercisable options	Weighted average remaining contractual life (years)	Weighted average exercise price (\$)	Expiry date
210,000 1,825,000	210,000 1,825,000	1.16 1.86	2.00 6.00	November 29, 2019 August 8, 2020
2,035,000	2,035,000	1.79	5.59	<u> </u>

12. LOSS PER SHARE

			E	e Months Ended ember 30, 2017	Six Months Ended September 30, 2018 2017				
Net loss for the period	\$	(3,751,014)	\$	(442,952)	\$	(8,290,714)	\$	(4,268,412)	
Net loss per share Basic Diluted	\$ \$	(0.10) (0.10)		(0.07) (0.07)		(0.21) (0.21)		(0.65) (0.65)	
Weighted average number of shares outstanding - basic and diluted		38,880,829		6,607,067		38,823,166		6,607,067	

⁽i) Diluted loss per share does not include the effect of warrants and stock options as they are anti-dilutive.

13. GENERAL AND ADMINISTRATIVE EXPENSES

	I	Ende	onths ed per 30,	E	nths ed oer 30,	
	2018		2017	2018		2017
Management and administrative services (Note 17) \$	887,809	\$	81,999	\$ 969,808	\$	163,998
Professional fees	876,379		(26,796)	1,601,539		823
Business advisory fees (1)	1,390,060		-	4,690,060		-
Office and administration	147,316		8,604	173,048		35,434
Travel expenses	135,979		1,587	137,744		3,174
Shareholders information	242,321		3,216	289,297		3,591
Regulatory fees	38,929		4,039	46,739		11,471
Share based compensation (Note 11)	2,518,500		-	2,518,500		-
Interest and penalty	-		11,204	-		18,141
Depreciation	1,948		2,457	3,896		4,914
	6,239,241	\$	86,310	\$10,430,631	\$	241,546

⁽¹⁾ Relates to advisory fees associated with the Company's key investment acquisitions.

Notes to Condensed Interim Consolidated Financial Statements Three and Six Months Ended September 30, 2018 (Expressed in Canadian Dollars, unless otherwise indicated) (Unaudited)

14. PREPAID DEPOSITS

The Company entered into a service agreement with a private company that has extensive experience working in Vietnam. The private company will provide due diligence services in regards to acquiring an investment in a mining operation in Vietnam. In fiscal year 2012, the Company paid a retainer of 1,100,000 GBP for the services. As of September 30, 2018, 118,353 GBP (C\$199,721) (March 31, 2018 - 118,353 GBP (C\$214,290)) of the initial deposit remained unused.

The Company is obligated to make another GBP1,100,000 (C\$1,894,750) deposit at the time the drilling phase of the project commences to maintain an interest in the operations.

15. CONTINGENCIES

From time to time, the Company is subject to legal proceedings and claims arising in the ordinary course of business. Management is of the opinion, based upon information presently available, that it is unlikely that any such liability, to the extent not provided for by insurance or otherwise, would have a material adverse effect in relation to the Company's financial position, liquidity, or results of operations.

16. SEGMENTED INFORMATION

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operation decision maker, or decision making group, in deciding how to allocate resources and in assessing performance.

The Company's reportable segments are based upon the geographic region for the Company's operations or tradable financial instruments, and include Canada, South Africa, Vietnam and Cyprus.

As at September 30, 2018, cash of \$18,740,945 (March 31, 2018 - \$21,296,842) was held in Canadian chartered banks. Total assets were held as follows:

As at September 30, 2018	Canada	Vietnam	South Afric	a	United State	s	Total
Current assets Equipment	\$ 41,780,529 34,240	\$ 199,721 -	\$ -	\$	20,258,026	\$	62,238,276 34,240
Other assets	-	-	-		47,182,930		47,182,930
Total assets	\$ 41,814,769	\$ 199,721	\$ -	\$	67,440,956	\$	109,455,446
As at March 31, 2018	Canada	Vietnam	South Africa	а	United State	es	Total
As at March 31, 2018 Current assets Equipment Other assets	\$ Canada 26,033,257 38,136	\$ Vietnam 214,290 - -	\$ - - 1,223,083		37,081,734 - 7,500,000		Total 63,329,281 38,136 8,723,083

Notes to Condensed Interim Consolidated Financial Statements Three and Six Months Ended September 30, 2018 (Expressed in Canadian Dollars, unless otherwise indicated) (Unaudited)

16. SEGMENTED INFORMATION (continued)

Three Months Ended September 30,	2018	Canada	Vietnam	South	Africa	a United Sta	tes Total
Net loss allocation for the period	\$(1	,484,459) \$	(3,634)	\$	-	\$ (2,262,92	1) \$(3,751,014)
Three Months Ended September 30,	2017	Canada	Vietnam	South	Africa	Cyprus	Total
Net loss allocation for the period	\$	24,625 \$	(2,308)	\$ (465	,269) \$	5 -	\$ (442,952)
Six Months Ended September 30, 20)18	Canada	Vietnam	South	Africa	United Sta	tes Total
Net loss allocation for the period	\$(4	,603,857) \$	(13,038)	\$	-	\$ (3,673,819	9) \$(8,290,714)
Six Months Ended September 30, 2	017 C	anada	Vietnam	South	Africa	Cyprus	Total
Net loss allocation for the period	\$	(72,641) \$	(7,016)	\$(4,188	3,755) \$	- -	\$(4,268,412)

17. RELATED PARTY TRANSACTIONS AND BALANCES

Related parties include the Board of Directors, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions.

Remuneration of directors and key management of the Company was as follows:

	Three Months Ended September 30,					Six Months Ended September 30,				
		2018		2017		2018	2017			
Directors fees (i)	\$	6,000	\$	6,000	\$	12,000 \$	12,000			
Alegana Enterprises Ltd. ("Alegana") (ii) 2249872 Ontario Ltd. (iii)		934,999 (53,190)		54,999 21,000		989,998 (32,190)	109,998 42,000			
Marrelli Support Services Inc ("MSSI") (iv)		4,500		4,500		9,000	9,000			
Alexander Dement'ev		30,000		-		30,000	-			
Share based compensation		517,500		-		517,500				
	\$	1,439,809	\$	86,499	\$	1,526,308 \$	172,998			

⁽i) Fees paid to directors of the Company. Included in accounts payable and accrued liabilities at September 30, 2018, is \$51,000 (March 31, 2018 - \$42,000) due to directors of the Company.

⁽ii) Alegana is a company controlled by Mr. John Zorbas, the President and Chief Executive Officer ("CEO") of the Company. The consulting fees paid to Alegana are for the function of the President which include, but are not limited to, managing the capital structure and current investment portfolio of the Company. Included in accounts payable and accrued liabilities at September 30, 2018 is \$1,671,366 (March 31, 2018 - \$669,150) owing to Alegana.

⁽iii) 2249872 Ontario Ltd. is a company controlled by Henry Kloepper, the former CEO of Captor. The management fees to 2249872 Ontario Ltd. were for the CEO function performed by Mr. Kloepper which includes the day-to-day operations of the Company as well as an implementation of the Company's long and short term plans. During the three and six months ended September 30, 2018, the Company reversed over accruals of \$53,190 and \$32,190, respectively. Included in accounts payable and accrued liabilities at September 30, 2018 is \$nil (March 31, 2018 - \$47,190) due to 2249872 Ontario Ltd.

Notes to Condensed Interim Consolidated Financial Statements Three and Six Months Ended September 30, 2018 (Expressed in Canadian Dollars, unless otherwise indicated) (Unaudited)

17. RELATED PARTY TRANSACTIONS AND BALANCES (continued)

- (iv) Mr. Jing Peng, the Chief Financial Officer ("CFO"), is a senior employee of MSSI. The management fees paid to MSSI relate to CFO function performed by Mr. Peng which includes the reporting of financial information and the safeguard of the Company's assets. Included in accounts payable and accrued liabilities at September 30, 2018 is \$7,760 (March 31, 2018 \$8,042) owing to MSSI.
- (v) Alexander Dement'ev, a director of Captor, was paid consulting fees for consulting services performed for the Company. Included in accounts payable and accrued liabilities at September 30, 2018 is \$5,650 (March 31, 2018 \$nil) due to Alexander Dement'ev.
- (vi) The Company is owed \$25,576 (March 31, 2018 \$25,576) from a company related to Captor through common management. These amounts are included in the amounts receivable and prepaid expenses balance on the statements of financial position.

18. FAIR VALUE MEASUREMENTS

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy establishes three levels to classify the inputs to valuation techniques used to measure fair value. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices in markets that are not active, quoted prices for similar assets or liabilities in active markets, inputs other than quoted prices that are observable for the asset or liability, or inputs that are derived principally from or corroborated by observable market data or other means. Level 3 inputs are unobservable (supported by little or no market activity). The fair value hierarchy gives the highest priority to Level 1 inputs and the lowest priority to Level 3 inputs.

(a) Assets and liabilities measured at fair value on a recurring basis:

As at September 30, 2018	Quoted price in active markets for entical asse (Level 1)	Significant other observable inputs (Level 2)	Significant unobservabl inputs (Level 3)	Aggregate fair value
Other investments Investment in MM Enterprises USA, LLC Investment in Chai Cannabis Inc. Investment in I-5 Holdings Ltd.	\$ 1,719,661 - - -	\$ - - -	\$ 525,000 12,425,000 7,833,026 47,182,930	\$ 2,244,661 12,425,000 7,833,026 47,182,930
	\$ 1,719,661	\$ -	\$ 67,965,956	\$ 69,685,617

Notes to Condensed Interim Consolidated Financial Statements Three and Six Months Ended September 30, 2018 (Expressed in Canadian Dollars, unless otherwise indicated) (Unaudited)

18. FAIR VALUE MEASUREMENTS (continued)

(b) Fair values of financial assets and liabilities:

		Septem	r 30, 2018	March 31, 2018				
		Carrying Estimated amount fair value			Carrying amount		Estimated fair value	
Loans and receivables								
Cash and cash equivalents (i)	\$	18,740,945	\$	18,740,945	\$	21,296,842	\$	21,296,842
Amounts receivable (i)		125,576		125,576		202,093		202,093
Loan receivable		19,911,570		19,911,570		1,344,602		1,344,602
	\$	38,778,091	\$	38,778,091	\$	22,843,537	\$	22,843,537
FVTPL								
Other investments	\$	2,244,661	\$	2,244,661	\$	2,936,757	\$	2,936,757
Investment in URU Metals Limited		-		-		1,223,083		1,223,083
Investment in MM Enterprises USA, LLC		12,425,000		12,425,000		37,081,734		37,081,734
Investment in Chai Cannabis Inc.		7,833,026		7,833,026		-		_
Investment in I-5 Holdings Ltd.		47,182,930		47,182,930		7,500,000		7,500,000
	\$	69,685,617	\$	69,685,617	\$	48,741,574	\$	48,741,574
Other financial liabilities								
Accounts payable and accrued liabilities (i	i)\$	2,198,513	\$	2,198,513	\$	1,426,375	\$	1,426,375
Loan payable `	, .	934,370		934,370		-	Ċ	
	\$	3,132,883	\$	3,132,883	\$	1,426,375	\$	1,426,375

⁽i) The carrying amounts of cash and cash equivalents, amounts receivable, loan receivable, accounts payable and accrued liabilities and loan payable are reasonable approximation of their fair values due to their shortterm nature.

The Company does not offset financial assets with financial liabilities.

19. SUBSEQUENT EVENTS

- (i) On October 15, 2018, the Company announced that it has signed a purchase agreement for Higher Level of Care dispensary in Castroville, California. The purchase is conditional on the successful transfer of Higher Level's license to sell recreational cannabis. Subject to the deal closing, the Company will pay a total purchase price of US\$2,875.000 to acquire Higher Level of Care, Castroville. Of the total purchase price, US\$1,500,000 will be paid upon the closing of the deal, while the remaining US\$1,375,000 shall be paid pursuant to a promissory note, which has been issued for a term of one year at an interest rate of 9% compounded monthly. In addition, the Company will make a cash payment for the cannabis inventory owned by the company, which will be determined upon the closing of the deal.
- (ii) On November 16, 2018, the Company announced that it has signed a definitive agreement ("the Agreement") to sell the retail operations and license for a dispensary location in Santa Ana, California, through an all-stock transaction with MedMen Enterprises valued at approximately US\$16 million. Upon closing, MedMen Enterprises will issue approximately 3,740,228 Class B Subordinate Voting shares (the "Shares") to Captor Capital. The final purchase price is subject to adjustment for accrued liabilities at the time of closing. The Agreement is subject to regulatory approvals by various local and state authorities and other customary closing conditions. The Company expects the transaction to close within 60 days.

Notes to Condensed Interim Consolidated Financial Statements Three and Six Months Ended September 30, 2018 (Expressed in Canadian Dollars, unless otherwise indicated) (Unaudited)

19. SUBSEQUENT EVENTS (continued)

(iii) On November 20, 2018, the Company announced that it has signed a Letter Of Intent to acquire an entity that has submitted an application pending approval for a cannabis dispensary in Santa Barbara County, California ("the Seller"). The transaction is subject to regulatory approval under the terms of the transaction. Captor shall acquire 99% of the equity interests in the Seller. The license is being sold for US\$1,300,000 (the "Purchase Price"). The Purchase Price for the entity that has applied for a cannabis dispensary license in Goleta, California is payable as follows: US\$250,000 shall be paid in cash on the date hereof, which shall be non-refundable to Captor (the "Deposit"); provided, however, in the event that the Company does not own, possess or is otherwise approved for the License on or before May 1, 2019, then the Deposit shall be refundable to Captor; US\$500,000 of the Purchase Price shall be paid in cash at the closing of the sale, which will occur upon regulatory approval; and US\$550,000 of the Purchase Price shall be payable in shares of the common stock of Captor, to be delivered after the 90th day following the closing of the transactions.